Passage Bio, Inc. (PASG) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Expected Frontotemporal Dementia (Progranulin Gene) Cohort 3 Patient Enrollment | 10.00 | FY2025-Q4 |
| Estimated Dose 2 Output per Single Batch (Suspension-Based Manufacturing Process) | 1K | FY2025-Q3 |
| Estimated PBFT02 Dose 2 Full Capsids Percentage | 70.00 percent | FY2025-Q3 |
| Estimated PBFT02 Dose 2 Purity | 90.00 percent | FY2025-Q3 |
| Good Manufacturing Practice Suspension-Based PBFT02 Manufacturing Execution Scale | 200.00 | FY2025-Q3 |
| Dose 2 PBFT02 Level as a Percentage of Dose 1 | 50.00 percent | FY2025-Q2 |
Back to PASG overview · PASG earnings · PASG holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.